2022 ARPA-E Energy Innovation Summit

COVID-19 Policy

In light of the on-going COVID pandemic, and to help ensure a healthy Summit environment, all Summit participants must provide ONE of the following documentation at the COVID-19 check-in desk prior to the Summit registration desk.

Participants’ must provide EITHER:

OR


The Centers for Disease Control and Prevention considers an individual fully vaccinated:
  • 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or
  • 2 weeks after a single-dose vaccine, such as Johnson & Johnson’s Janssen vaccine.

Note: Currently, participants will not be required to have a booster shot to attend the Summit.

Each Summit participant (attendee, exhibitor, and staff member) may be required to wear a mask at all times while indoors at the Summit, except while eating/drinking, should COVID community levels rise.

COVID-related measures for the Summit may be revised in keeping with any updates of federal, state, and local health guidelines.

Proof of Vaccination Documentation Requirements:
Attendees may provide a copy of the record of immunization from a health care provider or pharmacy, a copy of the COVID-19 Vaccination Record Card, a copy of medical records documenting the vaccination, a copy of immunization records from a public health or state immunization information system, or a copy of any other official documentation containing required data points (the required data points for such other official documentation are the type of vaccine administered, date(s) of administration, and the name of the health care professional(s) or clinic site(s) administering the vaccine(s)). Attendees may provide a digital copy of such records, including, for example, a digital photograph, scanned image, or PDF of such a record that clearly and legibly displays the information outlined above. Attendees must certify under penalty of perjury that the documentation they are submitting is true and correct.


Testing Requirements:
Any viral test authorized by the Food and Drug Administration is accepted as long as tests are not both self-administered and self-read. Accepted tests may be a nucleic acid amplification test (NAAT) or an antigen test. PCR tests are a type of NAAT. Tests may be a laboratory test or a rapid, point-of-care test. Options for testing methods include: (1) in-store or drive-through point-of-care testing, such as at pharmacies, (2) swab-testing capabilities that enable an individual to collect the specimen—using a self-collection kit—and drop it off at a designated collection location or ship it to a laboratory, (3) over-the-counter and other self-administered tests, as long as those tests are not both self-administered and self-read by the employee unless observed by an authorized telehealth provider.